Literature DB >> 28644949

Hematopoietic cell transplantation for acute lymphoblastic leukemia in adult patients.

Riad El Fakih1, Syed Ahmed2, Feras Alfraih2, Amr Hanbali2.   

Abstract

Acute lymphoblastic leukemia (ALL) consists of precursor B ALL or T ALL phenotypes. In the pediatric population, ALL patients enjoy an 80% long-term survival with the current pediatric chemotherapy protocols as compared with 50% long-term survival in the adult population. In adults, complete remission rates are similar to those of pediatric patients; however, long-term survival is much lower with the majority of deaths attributable to relapsed disease. Postremission consolidation strategies in adults include chemotherapy, autologous, or allogeneic transplant. Pediatric-inspired chemotherapy protocols are being explored as a consolidation modality in adults. Assigning patients to either modality depends on patient and disease characteristics. Here, we review the literature on the use of hematopoietic cell transplantation as a consolidation modality in the treatment of adult ALL.
Copyright © 2017 King Faisal Specialist Hospital & Research Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adult acute lymphoblastic leukemia; Allogeneic hematopoietic cell transplantation

Mesh:

Year:  2017        PMID: 28644949     DOI: 10.1016/j.hemonc.2017.05.015

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  3 in total

1.  Approach to the Adult Acute Lymphoblastic Leukemia Patient.

Authors:  Valentina Sas; Vlad Moisoiu; Patric Teodorescu; Sebastian Tranca; Laura Pop; Sabina Iluta; Sergiu Pasca; Cristina Blag; Sorin Man; Andrei Roman; Catalin Constantinescu; Ioana Rus; Mihail Buse; Bogdan Fetica; Mirela Marian; Cristina Selicean; Ioana Berindan-Neagoe; Bobe Petrushev; Horia Bumbea; Alina Tanase; Mihnea Zdrenghea; Shigeo Fuji; Shigehisa Kitano; Ciprian Tomuleasa
Journal:  J Clin Med       Date:  2019-08-06       Impact factor: 4.241

Review 2.  The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.

Authors:  Paniz Tavakoli Shirazi; Laura N Eadie; Susan L Heatley; Timothy P Hughes; David T Yeung; Deborah L White
Journal:  Br J Cancer       Date:  2019-12-03       Impact factor: 7.640

3.  PEDF promotes the repair of bone marrow endothelial cell injury and accelerates hematopoietic reconstruction after bone marrow transplantation.

Authors:  Wen Ju; Wenyi Lu; Lan Ding; Yurong Bao; Fei Hong; Yuting Chen; Hui Gao; Xiaoqi Xu; Guozhang Wang; Weiwei Wang; Xi Zhang; Chunling Fu; Kunming Qi; Zhenyu Li; Kailin Xu; Jianlin Qiao; Lingyu Zeng
Journal:  J Biomed Sci       Date:  2020-09-01       Impact factor: 8.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.